CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: P22077 exerts no cytotoxicity on normal CD34+ cells, but significantly inhibits the colony-forming activity of CD34+ cells from de novo and IM-resistant CML patients (Fig. 7j).